Wernet D, Schnaidt M, Mayer G, Northoff H
Department of Transfusion Medicine, University of Tübingen, FRG.
Vox Sang. 1993;65(2):108-13. doi: 10.1111/j.1423-0410.1993.tb02125.x.
Sera of hematologic-oncologic patients were tested regularly after platelet transfusions in three test systems: lymphocytotoxicity test, platelet adhesion immunofluorescence test, and--only selected sera--in the monoclonal antibody-specific immobilization of platelet antigen test. Of 388 patients 53 (14%) had HLA antibodies 5 of these in combination with platelet-specific alloantibodies. Lymphocyte-restricted (non-HLA) reactions were observed in 20 patients, the majority of which was attributed to lymphocyte-specific auto- or alloantibodies. Sera of 27 patients showed platelet-specific reactions, usually cold-reacting autoantibodies which have no effect in vivo.
在血小板输注后，采用三种检测系统定期检测血液肿瘤患者的血清：淋巴细胞毒性试验、血小板黏附免疫荧光试验，以及——仅对部分选定血清——血小板抗原单克隆抗体特异性固定试验。在388例患者中，53例（14%）有HLA抗体，其中5例同时伴有血小板特异性同种抗体。在20例患者中观察到淋巴细胞限制性（非HLA）反应，其中大多数归因于淋巴细胞特异性自身抗体或同种抗体。27例患者的血清显示血小板特异性反应，通常为在体内无作用的冷反应自身抗体。
